Artelo Biosciences (ARTL) News Today $1.19 -0.14 (-10.53%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$1.96 +0.77 (+64.45%) As of 05/22/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ARTL Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 Time Period Wall Street Zen Upgrades Artelo Biosciences (NASDAQ:ARTL) to "Sell"May 16, 2026 | americanbankingnews.comArtelo Biosciences Provides Business Update Outlining Upcoming Milestones and Reports 2026 First Quarter Financial ResultsMay 14, 2026 | markets.businessinsider.comArtelo Biosciences Announces Strategic Collaboration with Artificial Intelligence (AI) Leader ScienceMachine Highlighting New Expansion Opportunities and Insights for FABP5 ...April 28, 2026 | markets.businessinsider.comArtelo Biosciences Partners with ScienceMachine to Enhance FABP5 Inhibitor Development Through AI TechnologyApril 28, 2026 | quiverquant.comQArtelo Biosciences Announces Strategic Collaboration with Artificial Intelligence (AI) Leader ScienceMachine Highlighting New Expansion Opportunities and Insights for FABP5 Inhibitor DevelopmentApril 28, 2026 | globenewswire.comWhat's behind the rise in Artelo Biosciences stock?April 21, 2026 | msn.comWhat's Behind The Rise In Artelo Biosciences Stock?April 20, 2026 | benzinga.comArtelo Biosciences jumps after Nasdaq compliance update, with low-float volatility likely adding fuelApril 20, 2026 | quiverquant.comQArtelo Biosciences Highlights Promising Efficacy and Safety Profile of ART26.12 as a Novel Pain Treatment Ahead of Upcoming Clinical StudiesApril 20, 2026 | quiverquant.comQArtelo Announces Peer-Reviewed Publication Supporting its FABP5 Inhibitor ART26.12 as a Novel Pain Treatment with a Potentially First-in-Class ProfileApril 20, 2026 | globenewswire.comArtelo Biosciences Regains Compliance with Nasdaq Listing RulesApril 7, 2026 | quiverquant.comQArtelo Biosciences Regains Compliance with Nasdaq Listing RequirementsApril 7, 2026 | globenewswire.comArtelo Biosciences, Inc. Completes $11 Million Private Placement of Common Stock and WarrantsMarch 30, 2026 | quiverquant.comQArtelo Biosciences Announces Closing of $11.0 Million Private Placement Priced At-the-Market Under Nasdaq RulesMarch 30, 2026 | globenewswire.comArtelo Biosciences IncMarch 27, 2026 | cnn.comWhy did ARTL stock skyrocket over 141% pre-market today?March 27, 2026 | msn.comArtelo Biosciences shares surge as company pitches GLP-1 companion-therapy angle for ART27.13March 27, 2026 | quiverquant.comQArtelo Biosciences, Inc. Announces Private Placement of Common Stock and Warrants, Expected Proceeds of $11 MillionMarch 27, 2026 | quiverquant.comQArtelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq RulesMarch 27, 2026 | globenewswire.comArtelo Biosciences Stock Soars After Withdrawing SEC FilingMarch 27, 2026 | benzinga.comArtelo Biosciences Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 TreatmentsMarch 25, 2026 | globenewswire.comArtelo Biosciences Expands Clinical Pipeline into Glaucoma Market with Investigator-Sponsored StudyMarch 25, 2026 | quiverquant.comQArtelo Biosciences Expansion into $16.3B Glaucoma Market, Via Fully Funded Study, Highlights Multi-Platform Pipeline StrengthMarch 25, 2026 | globenewswire.comArtelo Biosciences moves into glaucoma research with fully funded clinical studyMarch 20, 2026 | msn.comWhy is ARTL stock soaring pre-market today?March 20, 2026 | msn.comArtelo Biosciences stock surges on glaucoma study agreementMarch 19, 2026 | za.investing.comNano-Cap Artelo Biosciences Stock Explodes — Glaucoma Study Collaboration Ignites RallyMarch 18, 2026 | benzinga.comBiotech Breakthroughs and Strategic Pivots Fuel Market MomentumMarch 18, 2026 | globenewswire.comVanderbilt Report: Artelo Biosciences Expands Into $16.3 Billion Glaucoma Market With Fully Funded Clinical StudyMarch 18, 2026 | globenewswire.comArtelo Announces Third-Party Fully Funded Clinical Study Agreement to Evaluate ART27.13 in Glaucoma PatientsMarch 18, 2026 | globenewswire.comArtelo Biosciences announces 3-for-1 reverse stock splitMarch 7, 2026 | finance.yahoo.comArtelo Biosciences Announces Reverse Stock SplitMarch 6, 2026 | globenewswire.comArtelo Biosciences Provides Business Update Highlighting Clinical Progress and Reports Fiscal 2025 Year-End Financial ResultsFebruary 24, 2026 | globenewswire.comArtelo Biosciences Secures Flexible Multiyear Equity FinancingFebruary 5, 2026 | tipranks.comArtelo Bioscience Commends Presidential Executive Order Expanding CBD Research and Access; Highlights ART12.11 as a Leading Pharmaceutical-Grade Cannabidiol CandidateDecember 23, 2025 | globenewswire.comArtelo Biosciences announces publication of research on SBFI103December 3, 2025 | msn.comArtelo Biosciences Announces Publication of New Peer-Reviewed Study Demonstrating Intraperitoneal Administration of a Novel Fatty Acid Binding Protein 5 (FABP5) Inhibitor ...December 3, 2025 | markets.businessinsider.comMaxim Group Downgrades Artelo Biosciences (ARTL)November 19, 2025 | msn.comArtelo Biosciences files to sell 899,972 shares of common stock for holdersNovember 18, 2025 | msn.comArtelo Biosciences Revises Bylaws, Alters Governance StructureNovember 14, 2025 | tipranks.comArtelo Biosciences Provides Business Update and Reports Third Quarter 2025 Financial ResultsNovember 12, 2025 | globenewswire.comArtelo Biosciences Publishes Article on FABP3's Role in Cancer in Drug Discovery TodayNovember 4, 2025 | quiverquant.comQArtelo Biosciences Announces Publication of Peer-Reviewed Article on Role of Fatty Acid Binding Proteins in CancerNovember 4, 2025 | globenewswire.comArtelo Biosciences appoints Mark Spring as Chief Financial OfficerOctober 27, 2025 | msn.comArtelo Biosciences Names Veteran Life Sciences Executive Mark Spring, CPA, as Chief Financial OfficerOctober 27, 2025 | globenewswire.comArtelo Biosciences Announces Expanded Clinical Data to be Presented on both ART26.12 and ART27.13 at the 8th Annual Cannabinoid & Endocannabinoid Drug Development SummitOctober 15, 2025 | globenewswire.comArtelo Biosciences Announces Closing of $2.0 Million Public OfferingOctober 1, 2025 | globenewswire.comArtelo Biosciences Announces Pricing of $2.0 Million Public OfferingSeptember 30, 2025 | globenewswire.comArtelo Biosciences files to sell common stock, no amount givenSeptember 29, 2025 | msn.comArtelo Biosciences, Inc. Announces Underwritten Public Offering of Common Stock and Pre-Funded WarrantsSeptember 29, 2025 | quiverquant.comQ Get Artelo Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ARTL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ARTL Media Mentions By Week ARTL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARTL News Sentiment▼0.000.44▲Average Medical News Sentiment ARTL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARTL Articles This Week▼13▲ARTL Articles Average Week Get the Latest News and Ratings for ARTL and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Artelo Biosciences and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies CDT Equity News Genprex News Addex Therapeutics News Ernexa Therapeutics News Bullfrog AI News NuCana News Creative Medical Technology News NKGen Biotech News Lunai Bioworks News Portage Biotech News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARTL) was last updated on 5/23/2026 by MarketBeat.com Staff. From Our PartnersYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artelo Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artelo Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
